Geode Capital Management LLC Grows Holdings in IDEXX Laboratories, Inc. $IDXX

Geode Capital Management LLC raised its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 3.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,583,939 shares of the company’s stock after acquiring an additional 86,263 shares during the quarter. Geode Capital Management LLC owned approximately 3.24% of IDEXX Laboratories worth $1,749,380,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Virtus Advisers LLC purchased a new stake in shares of IDEXX Laboratories during the 3rd quarter worth approximately $26,000. Park Place Capital Corp purchased a new stake in shares of IDEXX Laboratories during the 4th quarter worth approximately $29,000. WealthCollab LLC purchased a new stake in shares of IDEXX Laboratories during the 2nd quarter worth approximately $30,000. Greykasell Wealth Strategies Inc. purchased a new stake in shares of IDEXX Laboratories during the 3rd quarter worth approximately $35,000. Finally, Caitong International Asset Management Co. Ltd purchased a new stake in shares of IDEXX Laboratories during the 3rd quarter worth approximately $36,000. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

IDEXX Laboratories Stock Performance

NASDAQ IDXX opened at $568.03 on Friday. The company’s 50 day moving average is $564.85 and its 200-day moving average is $637.70. IDEXX Laboratories, Inc. has a 12-month low of $504.56 and a 12-month high of $769.98. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19. The firm has a market cap of $44.81 billion, a P/E ratio of 41.83, a price-to-earnings-growth ratio of 3.20 and a beta of 1.58.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.41 by $0.06. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The company had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.12 billion. During the same quarter in the previous year, the firm posted $2.91 earnings per share. The company’s quarterly revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Sell-side analysts predict that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on IDXX. Citigroup began coverage on shares of IDEXX Laboratories in a research note on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price target for the company. Weiss Ratings lowered shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 11th. UBS Group decreased their price target on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research note on Tuesday, April 28th. Wall Street Zen lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Finally, Barclays decreased their price target on shares of IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating for the company in a research note on Thursday, February 5th. Seven analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $751.00.

Insider Activity

In related news, EVP Nimrata Hunt sold 1,758 shares of the company’s stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $634.57, for a total transaction of $1,115,574.06. Following the sale, the executive vice president owned 18,141 shares of the company’s stock, valued at approximately $11,511,734.37. This represents a 8.83% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.79% of the stock is currently owned by company insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.